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Background. Vitamin A derivative all-trans retinoic acid (ATRA) is considered as a potent chemotherapeutic drug for its capability
of regulating cell growth and diﬀerentiation. We studied the eﬀect of ATRA on MMP-2 in MCF-7, human breast cancer cells,
and the probable signaling pathways which are aﬀected by ATRA on regulating pro-MMP-2 activity and expression. Methods.
Gelatin zymography, RT-PCR, ELISA, Western blot, Immunoprecipitation, and Cell adhesion assay are used. Results.G e l a t i n
zymography showed that ATRA caused a dose-dependent inhibition of pro-MMP-2 activity. ATRA treatment downregulates the
expression of MT1-MMP, EMMPRIN, FAK, NF-kB, and p-ERK. However, expression of E-cadherin, RAR, and CRABP increased
upon ATRA treatment. Binding of cells to extra cellular matrix (ECM) protein ﬁbronectin reduced signiﬁcantly after ATRA
treatment. Conclusions. The experimental ﬁndings clearly showed the inhibition of MMP-2 activity upon ATRA treatment. This
inhibitory eﬀect of ATRA on MMP-2 activity in human breast cancer cells (MCF-7) may result due to its inhibitory eﬀect on
MT1-MMP, EMMPRIN, and upregulation of TIMP-2. This study is focused on the eﬀect of ATRA on MMP, MMP-integrin-E-
cadherin interrelationship, and also the eﬀect of the drug on diﬀerent signaling molecules which may involve in the progression of
malignant tumor development.
Copyright © 2009 Anindita Dutta et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Retinoic acids, including vitamin A and its analogues, regu-
late the growth and diﬀerentiation. Retinoic acids suppress
tumor formation in animals and have shown to be eﬀective
chemotherapeutic agents in many cancers. Predominantly
all-trans retinoic acid (ATRA) and its stereoisomer 9-cis
retinoic acid were found to be very potent metabolites
of retinol exerting pleiotropic eﬀects on many diﬀerent
biological processes. In contrast to all-trans and 13-cis, 9-
cis retinoic acid has a greater eﬀect on cell morphology.
It has been reported that 13-cis retinoic acid decreases the
development of primary tumors in patients with head and
neck cancer, whereas ATRA provides a speciﬁc therapy for
acute promyelocytic leukemia [1, 2]. The antitumor eﬀect
of retinoids is most often attributed to the induction of
diﬀerentiation, but these compounds were also shown to
stop the growth of tumor cells by inducing apoptosis or
accelerated senescence [3]. The ability of retinoic acid to
induce diﬀerentiation in cancer cells suggests their potential
role as a cancer chemotherapeutic agent.
Retinoids exert their eﬀects by modulation of gene
expression by two distinct classes of nuclear receptors:
retinoic acid receptors (RAR α, β, γ) and rexinoid receptors
(RXR α, β, γ). The receptors belong to the steroids or
thyroid hormone super-family [4]. These receptors bear six
domains:A/Bforligand-independenttransactivation,Cwith
two zinc ﬁngers for DNA binding, D is a hinge region
and E is responsible for dimerization with RXR, ligand
binding, ligand-dependent transactivation, and association
with corepressor (CoR) or coactivators (CoA) complex. The
function of F is still not known [5]. Upon ligand binding,
receptors bind to retinoic acid response elements (RAREs),
speciﬁc DNA sequence, as receptor dimer. ATRA binds
with high aﬃnity (kd 0.2–0.4nM) to RARs, but not to
RXRs, whereas 9-cis retinoic acid binds to RXR with high2 Journal of Oncology
aﬃnity [4]. RARs may exist as homodimer and can form
heterodimer with RXRs as well and interact with RARE
[6, 7]. The receptor dimer complex remains silenced by
the binding of corepressors. Retinoid ligand binding to the
receptor dimer complex induces a conformational change
that removes the corepressors and recruits coactivators, thus,
facilitating initiation of transcription [8]. Two types of
cellular retinoic acid binding protein CRABP I and II can act
as transporter of retinoic acid to facilitate the transport of
cytoplasmic retinoic acid into the nucleus leading to ligand-
receptor interaction [4].
For tumor invasion and migration, the tumor cells
and host coordinately regulate matrix degradation, cell-
cell attachments, and cell matrix attachment. Aberrant
expression and activity of MMPs are associated with
malignant development of tumor cells [9]. Most of the
MMPs are secreted from cells in their inactive pro forms.
The activation mechanism usually involves cleavage of the
prodomain in the amino side of the conserved cystein
residue followed by opening of the active site through
the breakage of zinc-cystein bond [10]. The gelatinases
are distinguished by the presence of an FN-like region,
inserted in the catalytic domain. This insertion is important
in substrate recognition [11]. Among MMPs gelatinases
demonstrate speciﬁc cell-MMP interaction. For example,
MMP-2 binds to integrin αvβ3 and MMP-9 to CD44 [12].
Expression of integrin αvβ3 on the cell surface supports
maturation and activation of MMP-2 [13]. The membrane
bound MMPs (MT-MMPs) are characterized by a c-terminal
transmembrane portion and a short furin-like sequence
between the pro and the catalytic domain. The furin site
provides an alternative cleavage site for MMP activation
[14].
MMP activity can induce tumor growth or survival,
invasion, angiogenesis, and cell migration [15]. The expres-
sion of MMPs in tumor cells is regulated in a paracrine
manner. Tumor cells produce factors, such as chemokines,
cytokines, and the extra-cellular matrix metalloproteinase
inducer (EMMPRIN), which in turn upregulate MMPs [16].
MMPs are the main group of proteolytic enzymes that
facilitate tumor cell migration by degrading the basement
membrane and other components of extra-cellular matrix
(ECM)[17].BesidedegradationofECM,tumorcellinvasion
and migration rely on the receptor-dependent attachment
and release from the matrix and other cells. MMP activity
directly modulates the cell-cell and cell-matrix attachment
and regulates the process of cell invasion and migration [18].
Integrins play central role in anchorage-dependent growth,
apoptosis, diﬀerentiation, and migration. Integrins diﬀeren-
tiallyregulatetheproductionofMMPs.Inhumanmelanoma
cell lines, α5β1 integrin and αvβ3 integrin modulates release
of MMP-2 and subsequent invasive behaviour [19]. Reduc-
tion of cell adhesion is of major importance in tumor
metastasis and can be achieved by a variety of mechanisms
aﬀecting the E-cadherin-catenin complex. These include
reduction or loss of E-cadherin expression, mutation of the
genes of constituent molecules, redistribution of E-cadherin
within the cell and shedding of E-cadherin, and so forth,
[20].
In this communication, we report multifunctional eﬀect
of ATRA on (i) gelatinase-A expression and activity, (ii)
various signaling molecules, and (iii) the integrin group of
cell surface receptors in human breast cancer cells, MCF-7.
2.Materials
Minimal Essential Medium (MEM), Dulbecco’s Modi-
ﬁed Egal’s Medium (DMEM), and foetal bovine serum
(FBS) were purchased from Invitrogen Corporation, USA.
Fibronectin(440kDa)andproteinGagarosewerepurchased
from Roche, Germany. Gelatin Sepharose 4B beads was
purchased from Amersham Biosciences, USA. All-trans
Retinoic Acid (ATRA) was purchased from Sigma. Anti-
FAK,anti-TIMP-2,anti-NF-κB (p65),anti-EMMPRIN,anti-
MT1-MMP, anti-E-cadherin, anti-RAR, anti-CRABP, anti-
ERK, anti-phospho-ERK, and anti-VEGF antibodies were
purchased from Santa Cruz, USA. Alkaline phosphatase
coupled secondary antibodies (both monoclonal and poly-
clonal), HRP-coupled secondary antibody were purchased
from Calbiochem and Nitro blue tetrazolium/5-bromo-4-
chloro-3-indoyl phosphate (NBT/BCIP, western blue stabi-
lized substrate for alkaline phosphatase), and Tetramethyl
benzidine (TMB) was purchased from Bangalore Genei,
India. RNAqueous 4 PCR (Total RNA isolation kit) and
Retroscript (RT-PCR Kit) were purchased from Ambion,
USA. MMP-2, FAK, α5, β1 primers were purchased from
Operon, USA. GAPDH primers and 100 base pair DNA
ladder were from Genie, Bangalore.
3. Methods
3.1.CellCulture. A375humanmelanomacelllineandMCF-
7 human breast cancer cell line was obtained from National
Centre for Cell Sciences (NCCS), Pune, India. MCF-7 cells
were grown and maintained in MEM containing 10% FBS
and A375 cells were grown in DMEM supplemented with
10% FBS in a CO2 incubator at 37◦C.
3.2. Drug Treatment. 7.5mg Retinoic acid (purchased from
Sigma, USA) was dissolved in 5mL DMSO to prepare 5mM
stock solution. ATRA was added to the experimental dishes
at concentrations of 10, 20, 30μM.
3.3. Cell Viability Assay. A375 cells (300,000/mL) and MCF-
7 cells (300,000/1.5mL) were grown in serum free culture
medium (SFCM) in absence (Control) and in presence of
30μMA T R Af o r2 4( i nc a s eo fM C F - 7 )a n d4 8( i nc a s eo f
A375) hours. Control and ATRA-treated cells were collected
by trypsinization. 10μL of cell suspension (Control and
ATRA-treated) in PBS were taken and 10μLT ry p a nb l u ew a s
added into it. Cell suspensions were mixed well and kept for
3–5 minutes. A number of stained and unstained cells were
counted in a haemocytometer slide.
3.4. Zymography. MCF-7 cells (300,000/1.5mL) were ini-
tially grown in MEM supplemented with 10% FBS
in petridishes, washed with serum-free culture mediumJournal of Oncology 3
(SFCM),andtreatedwithincreasingconcentrationsofATRA
(10μM, 20μM, 30μM) for 24 hours in SFCM. Control cells
were grown without ATRA but in presence of 1% DMSO
(solvent for ATRA) for 24 hours and SFCM were collected.
The matrix metalloproteinases were separated from SFCM
using Gelatin Sepharose 4B beads and shaking for 2hours
at 4◦C. The beads were washed x3 with Tris-buﬀered saline
with Tween-20 (TBS-T) and suspended in 50μLo f1 X
sample buﬀer (0.075gm Tris, 0.2gm SDS in 10mL water,
pH 6.8). The suspension was incubated for 30 minutes at
37◦C and then centrifuged at 3000r.p.m. for 3 minutes.
The supernatant was then subjected to zymography on 7.5%
SDS-PAGEcopolymerizedwith0.1%gelatin.Gelwaswashed
in 2.5% Triton-X-100 for 30 minutes to remove SDS and
wasthenincubatedovernightinreactionbuﬀer(50mMTris-
H C lp H7 ,4 . 5m MC a C l 2, 0.2M NaCl). After incubation, the
gel was stained with 0.5% Coomassie blue in 30% methanol
and 10% glacial acetic acid. The bands were visualized by
destaining the gel with water.
3.5. Enzyme Linked Immunosorbent Assay (ELISA). MCF-
7 cells (300,000/1.5mL) were grown in serum-free culture
medium (SFCM) in absence (Control) and in presence
of 30μM ATRA (Experimental) for 24 hours. The culture
supernatants were collected by centrifugation at 3000r.p.m
f o r3m i n u t e s .T h ew e l l so fm i c r o t i t r ep l a t ew e r ec o a t e d
in triplicate with 50μL culture SFCM and with 50μg
protein from both control and experimental set and kept
at 4◦C overnight (plate was wrapped in wrap to prevent
evaporation). Blank wells (with buﬀer in which samples are
suspended) were also prepared. Next day wells were washed
with blocking buﬀer (1% BSA in PBS) to block nonspeciﬁc
binding sites and incubated for 1 hour at 37◦C. Then the
wellswerewashedthricewithWashingBuﬀer(0.5%NP-40&
0.5% BSA dissolved in PBS). Anti-TIMP-2, anti-E-cadherin,
anti-RAR, and anti-CRABP primary antibody solution (1 :
1000 dilution) was added to the wells and incubated at 37◦C
for 1 hour. Wells were washed thrice with Washing Buﬀer.
Respective second antibody solution (1 : 1000 dilution
buﬀer) was added to wells and incubated at 37◦Cf o r1
hour. Wells were washed six times with Washing Buﬀer (3–5
minutes per wash). Substrate (TMB) was added to the wells
(in darkness) and kept as long as required (i.e., until color
developed begins to become too intense). Then 1M H2SO4
stop solution was added and reading was taken in ELISA
reader at 450nm.
3.6. RT-PCR. RNA was extracted from 1 × 106 MCF-7 cells
grown in absence (Control) presence and of 30μMA T R A
for 24 hours. The sequence of the primers used for PCR
was: hMMP-2: 5 -GTA TTT GAT GGC ATC GCT CA-3 
(forward) and 5 -CAT TCC CTG CAA AGA ACA CA-3 
(reverse), hFAK: 5 -GCG CTG GCT GGA AAA AGA A-3 
(forward) and 5 -TCG GTG GGT GCT GGC TGG TAG G-
3  (reverse), hα5: 5 -CAT TTC CGA GTC TGG GCC AA-
3  (forward) and 5 -CAA AAC AGC CAG TAG CAA CAA-
3  (reverse), hβ1: 5 -TGT TCA GTG CAG AGC CTT CA-
3  (forward), and 5 -CCT CAT ACT TCG GAT TGA CC-
3  (reverse). GAPDH primers 5 -CGG AGT CAA CGG ATT
TGG TCG TAT-3  (forward) and 5 -AGC CTT CTC CAT
GGT GGT GAA GAC-3  (reverse) were used as control to
normalize for mRNA integrity and equal loading. RT-PCR
was carried out using two steps RT-PCR kit (Ambion, USA).
Components were incubated at 42◦Cf o r1h o u ra n da t
92◦C for 10 minutes (to inactivate the reverse transcriptase)
Conditions used for PCR consisted of 24 cycles for MMP-2
at 94◦C for 30 seconds, 63◦C for 30 seconds, and 72◦Cf o r
60 seconds, 25 cycles for FAK at 94◦C for 30 seconds, 60◦C
for 30 seconds and 72◦C for 1 : 30 minutes and 28 cycles
for α5&β1a t9 4 ◦C for 30 seconds, 58◦C for 30 seconds,
and 72◦C for 1 : 30 minutes with a ﬁnal incubation at 72◦C
for 7 minutes in DNA thermal cycler. The predicted size
of the PCR products were 198 base pairs (bp) for MMP-
2, 476bps for FAK, 324 for α5, 452 for β1, and 454 for
GAPDH.
3.7. Immunoblot Assay of MT1-MMP, EMMPRIN, FAK and
NF-κB. MCF-7 cells (300,000/1.5mL) were grown in serum
free culture medium (SFCM) in absence (control) and in
presence of 30μM ATRA for 24 hours. The respective cells
were collected. Cell extraction was carried out using cell
extraction buﬀer (37.5mM Tris, 75mM NaCl and 0.5%
Triton-X-100) and the protein content of the extracts were
estimated by Lowry’s method. Equal amount of protein was
taken and incubated with 1X sample buﬀer for 30 minutes
followed by 5–8 minutes incubation with 0.1 volumes β-
mercaptoethanol at 80–90◦C. Samples were then subjected
to electrophoresis on 7.5% SDS-PAGE. The proteins were
transferred on to nitrocellulose membranes by Western
Blot at 300mA for 3 hours. The membranes were blocked
with 1% BSA and subsequently washed thrice with TBS-T.
The immunoblots were reacted with anti-MT1-MMP, anti-
EMMPRIN, anti FAK, anti-NF-κB and anti-Ig-G antibodies,
respectively, (1 : 1000 dilution) for 1.5 hours at 37◦C
followed by incubation with respective alkaline phosphatase
coupled second antibodies. Bands were developed using
NBT-BCIP as substrate.
3.8. Immunoblot Assay of ERK, Phospho-ERK and VEGF
by Immunoprecipitation. MCF-7 cells (300,000/1.5mL) were
grown in serum-free culture medium (SFCM) in absence
(Control) and in presence of 30μM ATRA for 24 hours. The
cells were collected. Cell extraction was carried out using
the cell extraction buﬀer and the protein content of the
extracts was estimated by Lowry’s method. Equal amount
of protein was taken from each extract and ERK, VEGF
was immunoprecipitated from the extracts using anti-ERK,
anti-VEGF, and anti-Ig-G antibodies and protein-G agarose
beads and shaking overnight at 4◦C. The resultant immune-
complex was washed thrice in PBS, suspended in 1X sample
buﬀer and incubated at 37◦Cf o r3 0m i n u t e s ,f o l l o w e d
by incubation with 0.1 volumes of β-mercaptoethanol for
5–8 minutes at 80–90◦C. Samples were then subjected
to electrophorese on 7.5% SDS-PAGE. The proteins were
t r a n s f e r r e do nt on i t r o c e l l u l o s em e m b r a n eb yW e s t e r n
Blot. The membranes were blocked with 1% BSA and
subsequently washed thrice with TBS-T. The immunoblots4 Journal of Oncology
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Figure 1: Cell viability assay: MCF-7 (300,000cells/1.5mL) (Figure 1(a)) and A375 (300,000/mL) (Figure 1(b)) cells were grown in serum-
free culture medium (SFCM) in absence (Control) and in presence of 30μM ATRA (Treated) for 24 hours (Figure 1(a)) and 48 hours
(Figure 1(b)). Cells were collected and 0.4% trypan blue solution was added in both control and ATRA-treated cell suspension. Number of
blue cells and nonblue cells were counted and t-test was done to obtain the P-values. Zymographic analysis of pro-MMP-2 activity:M C F - 7
(300,000cells/1.5mL) cells were grown in serum-free culture medium (SFCM) in absence (control) (lane C) and in presence of 10 (lane
1), 20 (lane 2), 30 (lane 3) μM ATRA for 24 hours (Figure 1(c)). The culture supernatants were collected and MMPs were concentrated
using Gelatin-sepharose 4B beads. Gelatinases were eluted from bead with sample buﬀer and subjected to zymography on 7.5% SDS-PAGE
copolymerised with 0.1% gelatin. The zymogram was treated with 2.5% triton X-100 for 30 minutes followed by incubation in reaction
buﬀer for 20 hours and stained with coomassie blue. The quantitative measurement of the zymogram (Figure 1(c)) was performed by using
Image J Launcher (version 1.4.3.67). (C) shows the pro-MMP-2 activity in the SFCM of control cells. (1) is the representative of pro-MMP-2
activityintheSFCMof10μMATRA-treatedcells.(2)and(3)representsthepro-MMP-2activityintheSFCMof20and30μMATRA-treated
c e l l s( f o r2 4h o u r s ) ,r e s p e c t i v e l y .
were reacted with anti-ERK antibody, anti-phospho-ERK
antibody, anti-VEGF, and anti-Ig-G antibodies, respectively,
in 1 : 1000 dilution, and kept at 37◦C for 1.5 hours.
After washing with TBS-T, membranes were incubated with
alkaline phosphatase coupled respective second antibodies
(1 : 1000 dilutions). Bands were visualized using NBT/BCIP
as substrate.
3.9. Cell Adhesion Assay. The microtitre plate wells were
coated with ﬁbronectin (1.56μg, 3.125μg, 6.25μg, 12.5μg,Journal of Oncology 5
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Figure 2: ELISA of TIMP-2, E-cadherin, RAR and CRABP:M C F -
7 (300,000cells/1.5mL) cells were grown in serum free culture
medium (SFCM) in absence (C) and in presence of 30μMA T R A
(E) for 24 hours. The culture supernatants were collected and the
wells of an ELISA plate was coated with 50μL SFCM (for TIMP-
2) and 50μg of protein (for E-cadherin, RAR & CRABP) from
both control and ATRA-treated cells and kept at 4◦Cf o ro v e r n i g h t .
The next day contents of the wells were discarded and the wells
were washed with blocking buﬀer. Then 50μL of blocking buﬀer
was added to each well and kept at 37◦C for 1 hour. The blocking
buﬀer was discarded and the wells were washed with washing
buﬀer. The wells were then reacted with anti-TIMP-2 (Figure 2),
anti-Ecadherin (Figure 5(c)), anti-RAR (Figure 8(a)), anti CRABP
(Figure 8(b)) antibody, respectively, and kept in 37◦C for 1 hour.
The wells were washed with washing buﬀer and reacted with
respective HRP-coupled secondary antibody and kept in 37◦Cf o r
1 hour. The wells were washed with washing buﬀer and then TMB
substrate was added to each well for color development. The color
reaction was stopped with 1M H2SO4 s o l u t i o na n dO Do fe a c hw e l l
was measured at 450nm. The OD indicated the expression level of
TIMP-2(P = .000144(P<. 05))incontrolandtreatedMCF-7cells.
and 25μg ﬁbronectin/well). The ligands were allowed to
bind for 1.5 hours at 37◦C. Wells were blocked with Buﬀer
C( 1 %B S A ,1 m MC a C l 2,a n d1 m MM g C l 2 in PBS) for
1h o u ra t3 7 ◦C. Control and 30μMA T R A - t r e a t e d( f o r2 4
hours in complete medium) MCF-7 cells were trypsinised
from culture dishes, washed, suspended in Buﬀer C, added
to microtitre plates (50,000cells/well), and allowed to bind
at 37◦C for 1.5 hours. The wells were washed ×3w i t h
Buﬀer C. The bound cells were trypsinised, counted on
haemocytometer, and expressed as % of adhesion.
3.10. Statistical Analysis. Statistical analyses were done with
Student’s t-test comparing between the control and treated
groups.
4. Results
4.1. Eﬀect of ATRA on Cell Viability. Cell viability in MCF-
7( Figure 1(a)) cells before and after ATRA treatment was
checked using trypan blue stain (0.4%). In case of control
113 cells (average of 3 experiments) in 0.1μL( C o n t r o l )w e r e
counted as viable and in treated average of 3 experiments
showed 110 cells/0.1μL (Treated) were viable. However,
T-test showed that there was no statistically signiﬁcant
diﬀerence (P = .085) between two groups. Therefore, no
c h a n g e sw e r eo b s e r v e di nc e l lv i a b i l i t yo fc o n t r o la n dA T R A -
treated.
Figure 1(b) showed the cell viability in A375 cells. In
control, 138cells/0.1μL (average of 3 experiments) and
in treated 134cells/0.1μL (average of 3 experiments) were
viable. P = .113 indicates that there is no statistically
signiﬁcant diﬀerence in the cell viability of ATRA untreated
(Control) and ATRA-treated (Treated) cells.
4.2. Eﬀect of ATRA on Pro-MMP-2 Activity. The comparative
zymogram (Figure 1(c))o fc o n t r o l( l a n eC )M C F - 7c e l l sa n d
MCF-7 cells treated with 10μM (lane 1), 20μM( l a n e2 )
and 30μM (lane 3) ATRA for 24 hours showed appreciable
reduction in pro-MMP-2 activity in the SFCM of 30μM
ATRA-treated MCF-7 cells as compared to that of the
control. Pro-MMP-2 activity was not appreciably inhibited
after 10μMa n d2 0μMA T R At r e a t m e n tf o r2 4h o u r s .P r o -
MMP-2 activity of control and 30μMA T R A - t r e a t e d( f o r1 2
hours) MCF-7 cells in SFCM showed no appreciable change
in gelatinolytic activity.
4.3. Eﬀe c to fA T R Ao nT I M P - 2P r o t e i nE x p r e s s i o n . When the
culture supernatant from both control and 30μMA T R A -
treated MCF-7 cells were assayed for MMP-2 and tissue
inhibitorofMMP-2(TIMP-2)proteinbyELISA(Figure 2),it
wasfoundthatATRAsubstantiallyincreasedTIMP-2protein
level. P = .000144 (P<. 05) indicates data obtained are
highly signiﬁcant.
4.4. Eﬀect of ATRA on MT1-MMP Expression. To study the
status of pro-MMP-2 activation complex, we studied the
membrane type 1 MMP (MT1-MMP) expression by western
blot using anti-MT1-MMP polyclonal antibody. The result
(Figure 3(a)) showed that 30μMA T R A - t r e a t e d( l a n eE )
MCF-7 cells exhibit much lower expression of MT1-MMP
compared to the untreated MCF-7 cells (lane C).
4.5.EﬀectofA TRAonEMMPRINExpression. Treatment with
30μM ATRA for 24 hours (lane E) in MCF-7 cells showed
appreciable downregulation in EMMPRIN expression com-
pared to the control (lane C) as analyzed by western blot
(Figure 3(b)).
4.6. Eﬀect of ATRA on MMP-2 Gene Expression. To analyze
whether ATRA aﬀects MMP-2 by regulating at transcription
levels, we studied mRNA expression for MMP-2 by RT-
PCR. Figure 4 demonstrates a reduction in MMP-2 mRNA
expression after treating MCF-7 cells with 30μMA T R Af o r
24 hours (lane E) comparing the control (lane C).
4.7. Eﬀect of ATRA on Integrin Receptor—Ligand Interaction.
Figure 5(a) shows the eﬀect of 30μM ATRA for 24 hours
on adhesion of MCF-7 cells to ECM protein (ﬁbronectin).6 Journal of Oncology
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Figure 3: Western blot of MT1-MMP and EMMPRIN: MCF-7 (300,000cells/1.5mL) cells were grown in absence (lane C) and presence of
30μM ATRA (lane E) for 24 hours in SFCM. The cells were collected and were extracted in cell extraction buﬀer. 50μgo fp r o t e i nf r o m
both control and ATRA-treated cell extracts were run on 7.5% SDS-PAGE and the proteins were transferred onto nitrocellulose membrane
by western blot. The membrane was incubated with anti MT1-MMP (Figure 3(a)) and EMMPRIN (Figure 3(b)) antibody and then after
washingmembranewasincubatedwithrespectivealkalinephosphatasecoupledsecondaryantibody.BandswerevisualizedusingNBT-BCIP
as substrate. Ig-G was used as internal control. The quantitative measurement of the western blot (Figures 3(a) and 3(b)) was performed by
Image J Launcher (version 1.4.3.67). (C) is the amount of MT1-MMP and EMMPRIN expression in the control cells, respectively, and (E) is
the amount of MT1-MMP and EMMPRIN expression of 30μM ATRA-treated (for 24 hours) MCF-7 cells, respectively.
Binding of cells to ﬁbronectin decreased signiﬁcantly upon
ATRA treatment for 24 hours whereas binding of cells to
ﬁbronectin remained almost unaltered for 12 hours ATRA-
treated cells (result not shown).
4.8. Eﬀect of ATRA on α5 and β1 Integrin Receptor Expression.
RT-PCR analysis (Figure 5(b)) of control and ATRA-treated
cells showed signiﬁcant down regulation of α5 expression in
ATRA-treated cells. β1 expression was also downregulated
upon 30μMA T R At r e a t m e n tf o r2 4h o u r s .
4.9. Eﬀect of ATRA on E-Cadherin Expression. Figure 5(c)
represents the status of E-cadherin in control (C) and
30μM ATRA-treated (E) MCF-7 cells. When the expression
level of E-cadherin protein in control and 30μMA T R A -
treated (for 24 hours) were measured by ELISA, result
showed that E-cadherin expression increased signiﬁcantly
upon ATRA treatment. P = .01613 (P<. 05) indicates
statistically signiﬁcant diﬀerence in E-cadherin expression
between control and ATRA-treated cells.
4.10. Eﬀect of ATRA on FAK Expression. Focal adhesion
kinase (FAK) is located at the upstream of signaling cascade,
especially the integrin signaling pathway involves FAK. In
order to determine if ATRA aﬀect the FAK pathway in MCF-
7cells,cellswereculturedinabsence(laneC)andpresenceof
30μM ATRA (lane E) for 24 hours and FAK status was then
determined by RT-PCR and western blot analysis. Result
showed that FAK (Figures 6(a) and 6(b)) expression was
reduced upon ATRA treatment.
4.11. Eﬀect of ATRA on NF-kB Expression. Nuclear factor
kB (NF-kB) is one of the important signaling molecules
aﬀecting the activation of pro-MMP-2. Therefore, the status
of NF-kB in control (lane C) and 30μMA T R A( l a n eE )
treated MCF-7 cells was assayed by western blot. Figre 7(a) is
the representative of the western blot of NF-kB showed thatJournal of Oncology 7
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Figure 4: RT-PCR of MMP-2: MCF-7 (300,000cells/1.5mL) cells
w e r eg r o w ni na b s e n c e( l a n eC )a n di np r e s e n c eo f3 0μMA T R A
(lane E) for 24 hours in SFCM. Cells were washed in PBS and
total RNA were extracted (RNAqueous for PCR, Ambion). Two-
step RT-PCR (Retroscript, Ambion) was done with equal amounts
of total RNA using speciﬁc primers for MMP-2 PCR. 20μLo f
each PCR products were run on a 2.5% agarose gel and bands
visualised under UV. GAPDH primers were used to conﬁrm equal
loading. Documentation was done in Gel Doc (Image Master VDS,
Pharmacia, Biotech).
the expression of NF-kB protein was appreciably reduced
upon 30μM ATRA treatment for 24 hours in MCF-7 cells.
4.12. Eﬀect of ATRA on ERK and p-ERK. Figures 7(b) and
7(c) show the comparative ERK (Figure 7(b)) and p-ERK
(Figure 7(c)) expression by immunoprecipitation of ERK
and p-ERK from whole cell extract with anti ERK and anti
p-ERK antibodies followed by western blot. The results show
that ATRA treatment downregulates the phosphorylation of
ERK, but the ERK expression was not found to be altered
signiﬁcantly after ATRA treatment. The expression of p-ERK
is much less in the ATRA-treated (lane E) MCF-7 cell extract
compared with untreated (lane C) MCF-7 cell extract.
4.13. Eﬀect of ATRA on VEGF Expression. When the expres-
sion of VEGF protein was assayed in ATRA-treated (lane
E) and untreated (lane C) MCF-7 cells, western blot
(Figure 7(d)) demonstrated appreciable reduction in VEGF
protein expression in 30μM ATRA-treated MCF-7 cells,
compared to that of the control cells.
4.14. Eﬀe c to fA T R Ao nR A Ra n dC R A B PE x p r e s s i o n . ELISA
was performed to observe the status of RAR (Figure 8(a))
and CRABP (Figure 8(b)) upon ATRA treatment and it was
found that RAR and CRABP expression increased apprecia-
bly in 30μM ATRA-treated (E) MCF-7 cells, compared to
that of the control cells(C). P = .028 (P<. 05) indicates
that diﬀerences between control treated cells are statistically
signiﬁcant.
5. Discussion
In this communication we report the eﬀect of all-trans
retinoic acid (ATRA) on the expression and activity of
matrix metalloproteinases and possible mechanism that may
inﬂuence the drug to exert its eﬀect. Treatment of MCF-7
cellswithATRAshowedappreciableinhibitionofpro-MMP-
2 enzyme expression and activity. Treating cells with 30μM
ATRA showed signiﬁcant induction of the TIMP-2 protein
expression in the SFCM. The activity of MMPs in extra
cellular space is speciﬁcally inhibited by tissue inhibitors
of metalloproteinases (TIMPs). TIMPs bind to the highly
conserved zinc binding site of active MMPs at molar equiv-
alence. Over expression of TIMP-2 can inhibit the activity of
MMP-2 [21] and it also inhibits the invasive and metastatic
behaviorsofcancercells.Braunhutetal.showedthatretinoic
acid upregulated TIMP-2 expression in endothelial cells
[22]. Other studies also showed a pronounced induction
of the TIMP-1 protein by vitamin A [23, 24]. RT-PCR
result demonstrates appreciable reduction of MMP-2 gene
expression upon 30μMA T R At r e a t m e n tf o r2 4h o u r s .
Therefore, ATRA could suppress the gelatinolytic enzyme
activity by regulating MMP-2 gene transcription. Pro-MMP-
2 is activated at the cell surface through a unique multistep
pathway that involves αvβ3 integrin, MT1-MMP and TIMP-
2. MT1-MMP acts as receptor and activator for pro MMP-2.
However, MT1-MMP cannot bind pro MMP-2 directly, and
TIMP-2 acts as an adaptor molecule to mediate pro MMP-
2 binding by forming ternary complex. The N-terminal
domain of TIMP-2 binds the hemopexin like domain of pro
MMP-2.CleavageofproMMP-2requiresthepresenceoffree
MT1-MMP in addition to the complex [25, 26]. Our results
demonstrate ATRA mediated reduction of MT1-MMP pro-
tein expression which may cause reduced activation of pro-
MMP-2 in ATRA-treated MCF-7 cells. Extracellular matrix
metalloproteinaseinducer(EMMPRIN),a58kDtype-Itrans
membrane protein is known to play role in ECM remodeling
through the activation of MMP production [27]. EMMPRIN
exhibits potential to induce MMP-2 expression [28]. In this
study downregulation of EMMPRIN expression by ATRA
may cause reduced pro-MMP-2 activity in the SFCM of
ATRA-treated MCF-7 cells.
The interaction of cells with adhesion protein in the
ECM provides signals which aﬀect the morphology, motility,
gene expression and survival of adherent cells [29]. The rela-
tionship that exists between integrin receptor, ﬁbronectin,
and MMP expression is of particular interest. Fibronectin
is a prototype cell adhesion protein. It is present as a
polymeric ﬁbrillar network in the ECM and as soluble
protomer in body ﬂuids. Two regions in each ﬁbronectin
subunit possess cell binding activity: III9-10 and III14-V.T h e
RGD motif in ﬁbronectin is located in III10 and is the
most important recognition site for most of the known
integrins [30]. Integrins, a family of cell surface receptors,
mediate attachment of the cells to ECM and initiate a
series of signaling events that ultimately activates proteases
like gelatinases. Integrins mediate both cell-cell and cell-
substratum adhesion and signaling [29, 31]. Binding of
integrin receptors to ﬁbronectin can initiate organization of
the cytoskeleton and focal contacts and signals which aﬀect
gene expression. Fibronectin through interaction with its
corresponding α5β1 integrin receptor regulate the activity
and expression of MMP-2 and MMP-9 [32–34]. On bind-
ing to ECM molecules, integrins are thought to undergo
a conformational change, which allows the intracellular
domain of their β subunit to interact with focal adhesion
proteins. FAK appears to localize to nascent focal adhesions.
Upon activation, FAK combines with Src and FAK/Src8 Journal of Oncology
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Figure 5: (a) Cell Adhesion Assay: MCF-7 cells (300,000cells/1.5mL) were grown in absence (Control) and in presence of 30μMA T R Af o r
24 hours in 10% MEM. Microtitre wells were coated with various concentrations of ﬁbronectin and kept at 37◦C for 1.5 hour. 1% BSA
solution was used to block the nonspeciﬁc sites. Control and ATRA-treated cells were collected by trypsinization and 50,000 cells were added
to each well. After 1 hour of incubation wells were washed thoroughly, number of bound cells was counted on a haemocytometer, and the
% of cells adhered to the ligand was calculated. (b) RT-PCR ofα5&β1: MCF-7 (300,000 cells/5mL) cells were grown in absence (lane C)
and in presence of 30μM ATRA (lane E) for 24 hours in SFCM. Two steps RT-PCR (Retroscript, Ambion) was done as before with equal
amountsoftotalRNAusingspeciﬁcprimersforα5&β1.GAPDHwasusedasinternalcontrol.(c)ELISAofE-cadherin:ELISAofE-cadherin
was performed with anti-E-cadherin antibody in control (C) and ATRA treated (E) MCF-7 cells. P = .01613 (P<. 05) indicates that the
diﬀerence in E-cadherin expression between control and ATRA treated MCF-7 cell is statistically signiﬁcant.
signaling pathway and promotes cell migration [35, 36].
Our study demonstrates that treatment of MCF-7 cells with
ATRA downregulates the expression of α5a n dβ1w h i c h
reﬂects the result of cell adhesion assay, showing reduced
tumor cell binding to ECM protein ﬁbronectin after ATRA
treatment in a time dependent manner. Our earlier study
showed that ATRA treatment downregulates α5 and β1
subunit expressions of α5β1 receptor in SiHa cells [37].
Focal adhesion kinase (FAK) was ﬁrst shown to be linked to
integrin signaling when it was identiﬁed as a major substrateJournal of Oncology 9
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Figure 6: (a) Western blot analysis of FAK: MCF-7 (300,000cells/1.5mL) cells were grown in absence (lane C) and presence of 30μMA T R A
(lane E) for 24 hours in SFCM. The cells were collected and were extracted in cell extraction buﬀer. 50μg of protein from both control and
ATRA-treated cell extracts were run on 7.5% SDS-PAGE and the proteins were transferred onto nitrocellulose membrane by western blot.
Themembranewasincubatedwithanti-FAKantibodyfollowedbyincubationwithalkalinephosphatasecoupledsecondaryantibody.Bands
were visualized using NBT-BCIP as substrate. Quantitative measurements of immunoblot was done by using Image J Launcher (version
1.4.3.67). (C) represents the expression of respective proteins in control cells whereas (E) represents expression in 30μM ATRA treated cells.
(b) RT-PCR of FAK: Figure 6(b) showed the status of FAK mRNA expression in control (lane C) and ATRA treated (lane E) MCF-7 cells. A
quantitative measurement of RT-PCR (Figure 6(b)) was done by using Image J Launcher (version 1.4.3.67). (C) represents the expression of
FAK in control cells whereas (E) represents FAK expression 30μM ATRA treated cells in respective ﬁgures.
for tyrosine phosphorylation. It has been suggested that Rho,
a Ras-like GTP binding protein that regulates the formation
of focal adhesions and actin stress ﬁbers, may be involved
in the activation of FAK. Thus, multiple cancer cell survival
stimuli that signal through diverse pathways converge to
induce the tyrosine phosphorylation of a common substrate,
FAK [38]. Furthermore, FAK induces MMP-2 secretion from
cell interior to its medium [39, 40]. ATRA treatment caused
a signiﬁcant decrease in FAK expression in MCF-7 cells. It
may contribute to the cell motility and decreased gelatinase
activity by regulating the secretion of MMP-2 in the SFCM.
Alterations in the adhesion properties of neoplastic cells
may play a pivotal role in the development and progression
of the malignant phenotype in a range of tumor types.
Adhesion molecules are intimately involved in the control
of such processes as morphological diﬀerentiation, cellular
proliferation,andinvasionandcolonizationatdistantorgans
[41]. E-cadherin dependent cell-cell adhesion is important
for the maintenance of epithelial structural integrity and the
loss of E-cadherin expression has been shown to correlate
with increased invasive potential of both carcinoma cell lines
and human tumor samples [42]. Recent data demonstrate
thattumor-associatedMMPscanmodulatecell-celladhesion
by cleaving E-cadherin [43]. Evidence is emerging that there
may be cross-talk between the cadherins and the integrins.
Anticadherin antibodies have been shown to prevent the
loss of α6a n dβ1 integrins in terminally diﬀerentiating
keratinocytes [44]. Positive expression of E-cadherin could
decrease cell adhesion to ﬁbronectin partially through tran-
scriptional inhibition of α5β1 integrin gene [45]. Our results
showed that ATRA treatment up-regulated E-cadherin
expression in MCF-7 cells which could downregulate the α5
and β1 expression and possibly attributed to inhibition of
cell-matrixadhesionandthereforeinturninhibitpro-MMP-
2 activity. Overexpression of E-cadherin decreased MMP-2
activity in prostate cancer cells and MT1-MMP in squamous
cancer cells [46]. Therefore, overexpression of E-cadherin in
ATRA-treated MCF-7 cells may downregulate pro-MMP-2
activity in the SFCM of ATRA-treated cells.
In our study, we found decreased expression of NF-κB
in ATRA-treated MCF7 cells. NF-κB is active in nucleus
and is inhibited through its sequestration in the cytoplasm
by inhibitor of κB( I κB). IκB kinase (IKK) can degrade
IκB and thus release NF-κB from inhibition [47]. NF-κB
mediates MT1-MMP induction and pro-MMP-2 activation.
Osteopontin, a membrane protein induces NF-κB mediated
pro-MMP-2 activation through IκBα/IKK phosphorylation
[48].Therefore,bysuppressingtheNF-κBproteinexpression10 Journal of Oncology
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Figure 7: (a) Western blot of NF-kB: NF-kB expression in control (lane C) and ATRA treated (lane E) MCF-7 cells was observed by western
blotanalysisasbeforeusinganti-NF-κBprimaryantibody.QuantitativemeasurementsofimmunoblotsweredonebyusingImageJLauncher
(version 1.4.3.67). (C) represents the expression of respective proteins in control cells whereas (E) represents expression in 30μMA T R A
treated cells. (b), (c), and (d) Immunoblot assay of ERK, p-ERK, and VEGF: MCF-7 cells (300,000cells/1.5mL) were grown in absence
(lane C) and presence of 30μM ATRA (lane E) for 24 hours in SFCM. Cells were collected and extracted in cell extraction buﬀer. ERK
and PI-3K were immunoprecipitated from 150μg of protein from both control and ATRA-treated cell extract with anti-ERK & protein G
Agarose bead (Figures 7(b) and 7(c)) and with anti-VEGF & protein G Agarose bead (Figure 7(d)), keeping the samples for overnight at
4◦C with shaking. In each case the resultant immune complex was washed thrice with PBS and the respective protein bound with antibody
were eluted from the agarose bead using 1X sample buﬀer. Samples were then incubated in β-mercaptoethanol for 10 minutes at 90◦C.
Samples were subjected to electrophoresis on 7.5% SDS-PAGE. The proteins were transferred to nitrocellulose membrane by Western Blot.
The membranes were incubated with anti-ERK (Figure 7(b)), anti-phospho ERK (Figure 7(c)), and anti-VEGF antibody (Figure 7(d)),
respectively. The immunoblots were then incubated with alkaline phosphatase-coupled secondary antibodies and bands were visualized by
NBT/BCIP substrate. Ig-G (Figure 7(e)) was used to conﬁrm equal loading. Quantitative measurements of immunoblots were done by using
Image J Launcher (version 1.4.3.67). (C) represents the expression of respective proteins in control cells whereas (E) represents expression
in 30μM ATRA treated cells.
ATRA may downregulate pro-MMP-2 activation. Further-
more, constitutive activation of NF-κB may very well play
an anti-apoptotic role in the breast and prostate carcinoma
cells [49]. The inhibition of constitutive NF-κBa c t i v a t i o n
by reducing NF-κB expression in ATRA-treated MCF-7 cells
may therefore enhance the basal apoptotic rate in these cells.
Dual speciﬁcity phosphatase 6 (DUSP6) dephospho-
rylates activated ERK and blocks the growth stimulatoryJournal of Oncology 11
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Figure 8: ELISA of RAR & CRABP: The status of RAR (Figure 8(a))a n dC R A B P( Figure 8(b)) in control (C) and ATRA treated (E) MCF-7
cells were analysed by ELISA as before using anti-RAR and anti-CRABP primary antibody and respective secondary antibodies. The OD
indicates the expression level of RAR (Figure 8(a); P = .028334 (P<. 05))a n dC R A B P( Figure 8(b); P = .028 (P<. 05)) in whole cell
extract.
signals. DUSP6 and RGS16 (regulator of G-protein signaling
16) transcriptional upregulation inhibits tumor cell prolif-
eration and ERK phosphorylation and serves as a negative
regulatory mechanism to prevent further ERK phosphoryla-
tion. Liu et al. showed RA induced upregulation of DUSP6
&R G S 1 6[ 50]. Our study demonstrates decreased p-ERK
level in ATRA-treated cells. Reduced ERK phosphorylation
mayresultduetoATRAinducedtranscriptionalactivationof
DUSP6 and RGS16. Activation of ERK plays an essential role
in the expression of MT1-MMP [51, 52]. Reduced activation
of ERK may cause lesser expression of MT1-MMP in ATRA-
treated cells.
Angiogenesis is known to be one of the most important
aggravating steps in the progression of cancer. Various
angiogenic factors are known to be upregulated in cancer.
Some of the proangiogenic factors such as thrombin, H2O2,
hepatocytegrowthfactors,vascularendothelialgrowthfactor
(VEGF) are known to have contribution to the activation
and release of MMP-2 [53, 54]. Upon ligand (VEGF)
binding to its receptor VEGFR-2 tyrosine kinase signal-
ing cascade gets stimulated. As a result of this signaling
cascade, proliferation/survival factors (bFGF), migration
factors (ICAMs/VCAMs/MMPs), and vessel permeability
factors (eNOs) are produced [55]. Downregulation of VEGF
expression in ATRA-treated MCF-7 cells may contribute to
the reduced pro-MMP-2 activity in treated cells.
All-trans retinoic acid after entering into the cell, its
entry from cytoplasm to nucleus is facilitated by CRABP I/II.
In the nucleus it binds with its speciﬁc receptor RAR/RXR
and exerts its eﬀect by regulating various gene transcrip-
tions. Several studies suggested that RAR/RXR and CRABP
expression gotincreasedwhencellsreceivedATRAtreatment
[56, 57]. Our study also demonstrates up-regulation of RAR
and CRABP expression upon ATRA treatment in MCF-7
cells.
In conclusion, the present study demonstrates the
inhibitory eﬀect of ATRA on pro-MMP-2 activity and the
possible molecular mechanisms. Our experimental ﬁndings
strongly indicate that ATRA induced inhibition of pro-
MMP-2 activity may result due to increased expression of
TIMP-2, and downregulation of FAK, MT1-MMP, EMM-
PRIN, and NF-kB expression. ATRA may interfere with the
integrin down-stream signaling altering the expression and
activity of pro-MMP-2.
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